<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04748211</url>
  </required_header>
  <id_info>
    <org_study_id>2017-116-06/12</org_study_id>
    <nct_id>NCT04748211</nct_id>
  </id_info>
  <brief_title>Effect of Infraclavicular and Interscalen Block on Oxygenitaon of the Forearm</brief_title>
  <official_title>Effect of Infraclavicular and Interscalen Block on Oxygenitaon of the Forearm : Randomized Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bulent Ecevit University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bulent Ecevit University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      to research the oxygenitaon effects of infraclavicular and interscalene blocks on the&#xD;
      forearm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To research the oxygenation effects of infraclavicular and interscalen blocks on the forearm&#xD;
      by comparing the blood flow (BF) values using the USG, Perfusion index (PI) and Near infrared&#xD;
      spectroscopy (NIRS) values using the massimo device.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Actual">June 15, 2019</completion_date>
  <primary_completion_date type="Actual">June 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study will be a two-arm parallel assignment. One group will receive infraclavicular block and the other will receive interscalen block</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>oxygenation of the forearm</measure>
    <time_frame>during the procedure three times</time_frame>
    <description>to compare the oxygenation of the forearm by measuring perfusion index device</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Upper Extremity Fracture</condition>
  <arm_group>
    <arm_group_label>Infraclavicular Block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group I received USG and neurostimulator guided infraclavicular block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interscalen Block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group II received USG and neurostimulator guided interscalen block. 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Infraclavicular Block</intervention_name>
    <description>USI and neurostimulator guided infraclavicular block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.</description>
    <arm_group_label>Infraclavicular Block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Interscalen Block</intervention_name>
    <description>USI and neurostimulator guided interscalen block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.</description>
    <arm_group_label>Interscalen Block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged between 18-65&#xD;
&#xD;
          -  ASA Score I-III&#xD;
&#xD;
          -  undergoing elective or emergency arm, elbow and forearm surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient's refusal for Brachial Plexus Blockage&#xD;
&#xD;
          -  Patients who had any neurological disorders preventing the evaluation of the sensory&#xD;
             block in the upper extremity,&#xD;
&#xD;
          -  Infection in the area to be blocked with ICB or ISB,&#xD;
&#xD;
          -  Non-cooperated patients&#xD;
&#xD;
          -  Patients with coagulopathy,&#xD;
&#xD;
          -  Morbidly obese patients&#xD;
&#xD;
          -  Patients with diabetes mellitus&#xD;
&#xD;
          -  Patients with hypertension&#xD;
&#xD;
          -  Patients with peripheral artery disease&#xD;
&#xD;
          -  Patients with allergy to the drugsto be used&#xD;
&#xD;
          -  Patients who had trauma in the area scheduled for the block&#xD;
&#xD;
          -  Paitens who had deterioration of anatomical integrity because of previous surgery&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Patients whose block failed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eren Açıkgöz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bulent Ecevit University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zonguldak Bulent Ecevit University</name>
      <address>
        <city>Zonguldak</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bulent Ecevit University</investigator_affiliation>
    <investigator_full_name>OZCAN PISKIN, MD</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

